Fenoldopam Use in a Burn Intensive Care Unit: A Retrospective Study

摘要

Fenoldopam mesylate is a highly selective dopamine-1 receptor agonist approved for the treatment of hypertensive emergencies that may have a role at low doses in preserving renal function in those at high risk for or with acute kidney injury (AKI). There is no data on low-dose fenoldopam in the burn population. The purpose of our study was to describe our use of lowdose fenoldopam (0.03/0.09 micrograms/kg/min) infusion in critically ill burn patients with AKI.a.